Shandong Xinhua Pharmaceutical Granted Drug Registration Certificate for Entacapone Tablets

Stock News

03/04

Shandong Xinhua Pharmaceutical (00719) announced that it has recently received the Drug Registration Certificate for Entacapone Tablets from the National Medical Products Administration. The product serves as an adjunct therapy to standard medications such as levodopa/benserazide or levodopa/carbidopa, intended for the treatment of Parkinson's disease and end-of-dose symptoms that are not adequately controlled by these drugs. Entacapone Tablets are classified as a Category B drug in the National Reimbursement Drug List for basic medical insurance, work-related injury insurance, and maternity insurance (2025). According to relevant statistics, sales of Entacapone Tablets in China's public medical institutions reached approximately RMB 286 million in 2024. The recent approval of Entacapone Tablets expands Shandong Xinhua's product portfolio and is expected to enhance the company's overall competitiveness.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1178574727"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1178574727\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1178574727?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 16:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178574727","market":"us","top_or_hot":-1,"title":"Shandong Xinhua Pharmaceutical Granted Drug Registration Certificate for Entacapone Tablets","media":"Stock News","content":"<p>Shandong Xinhua Pharmaceutical (00719) announced that it has recently received the Drug Registration Certificate for Entacapone Tablets from the National Medical Products Administration. The product serves as an adjunct therapy to standard medications such as levodopa/benserazide or levodopa/carbidopa, intended for the treatment of Parkinson's disease and end-of-dose symptoms that are not adequately controlled by these drugs. Entacapone Tablets are classified as a Category B drug in the National Reimbursement Drug List for basic medical insurance, work-related injury insurance, and maternity insurance (2025). According to relevant statistics, sales of Entacapone Tablets in China's public medical institutions reached approximately RMB 286 million in 2024. The recent approval of Entacapone Tablets expands Shandong Xinhua's product portfolio and is expected to enhance the company's overall competitiveness.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shandong Xinhua Pharmaceutical Granted Drug Registration Certificate for Entacapone Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShandong Xinhua Pharmaceutical Granted Drug Registration Certificate for Entacapone Tablets\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-03-04 16:34</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shandong Xinhua Pharmaceutical (00719) announced that it has recently received the Drug Registration Certificate for Entacapone Tablets from the National Medical Products Administration. The product serves as an adjunct therapy to standard medications such as levodopa/benserazide or levodopa/carbidopa, intended for the treatment of Parkinson's disease and end-of-dose symptoms that are not adequately controlled by these drugs. Entacapone Tablets are classified as a Category B drug in the National Reimbursement Drug List for basic medical insurance, work-related injury insurance, and maternity insurance (2025). According to relevant statistics, sales of Entacapone Tablets in China's public medical institutions reached approximately RMB 286 million in 2024. The recent approval of Entacapone Tablets expands Shandong Xinhua's product portfolio and is expected to enhance the company's overall competitiveness.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"製藥","start_time":0,"source_url":"","article_id":"1178574727","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178574727","pubTimestamp":1772613259,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shandong Xinhua Pharmaceutical (00719) announced that it has recently received the Drug Registration Certificate for Entacapone Tablets from the National Medical Products Administration. The product...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1515":"抗疫概念","00719":"山东新华制药股份"},"translate_title":"山东新华制药获恩他卡朋片药品注册证书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00719":1},"content_text":"Shandong Xinhua Pharmaceutical (00719) announced that it has recently received the Drug Registration Certificate for Entacapone Tablets from the National Medical Products Administration. The product serves as an adjunct therapy to standard medications such as levodopa/benserazide or levodopa/carbidopa, intended for the treatment of Parkinson's disease and end-of-dose symptoms that are not adequately controlled by these drugs. Entacapone Tablets are classified as a Category B drug in the National Reimbursement Drug List for basic medical insurance, work-related injury insurance, and maternity insurance (2025). According to relevant statistics, sales of Entacapone Tablets in China's public medical institutions reached approximately RMB 286 million in 2024. The recent approval of Entacapone Tablets expands Shandong Xinhua's product portfolio and is expected to enhance the company's overall competitiveness.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}